drugset
drugset / Trial / NCT02843074

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

NCT02843074 ↗

Phase 2 Completed 53 enrolled SCRI Development Innovations, LLC Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2, single arm, open-label, multicenter study to evaluate the feasibility and tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment of transplant eligible, newly diagnosed multiple myeloma patients.

Timeline

Start
2016-09-21
Primary completion
2021-07-27
Completion
2021-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 8 mg Oral
Subject Dexamethasone Small molecule 28 mg Oral
Subject Elotuzumab Monoclonal antibody 20 mg/kg Intravenous
Subject Lenalidomide Other / unclassified 10 mg Oral

Indications

plasma cell myeloma